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Thyroxine-induced epilepsy is a very rare condition occurring in epileptic patients. Here we report a boy with thyroxine-induced
hypermotor seizure (HMS) following thyroxine administration for his central hypothyroidism secondary to surgery and cranial
radiation for his brain tumor. After 3 years seizure-free period, he had repeated HMS, seven to eight attacks per day, after
initiation l-thyroxine treatment. Following reduction of the daily thyroxine dose, his seizures decreased in frequency. To our
knowledge, this is the first reported case of HMS associated with l-thyroxine administration.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Thyroxine lowers the seizure threshold of experi-
mental animal models1, 2, produces high amplitude
photic response in healthy volunteers3 and caused
seizures in patients with Graves’ disease4. Previ-
ously, l-thyroxine-induced petit mal status epilepticus
and, absence seizures in juvenile myoclonic epilepsy
(JMCE) were reported in two different studies5, 6.
But, seizure due to thyrotoxicosis and, thyroid storm
presenting with seizures was notified different study
in pediatric patients7–9.
In the semiologic seizure classification hypermotor
seizures (HMSs) are defined as seizures consisting of
complex, organised movements which affect mainly
the proximal portion of the limbs and lead to a marked
increase in motor activity and most frequently associ-
ated with frontal lobe10.
We describe a patient with partial secondary gener-
alised tonic–clonic seizures (GTCS), well controlled
by carbamazepine and phenobarbital treatment in
whom HMS were provoked by l-thyroxine adminis-
tration without affecting the frequency or severity of
his GTCS.
CASE REPORT
An 11-year-old boy with operated anaplastic oligo-
dendrogliotic tumor was brought to Department of Pe-
diatrics, Dokuz Eylül University Faculty of Medicine
with the complaint of seizures for the last 1 month. He
had been diagnosed with anaplastic oligodendrogli-
otic tumor (left frontal lobe) 5 years ago when he first
presented with acute confusional state and headache.
Post-operatively he had no neurological deficits or
seizures. He began phenytoin treatment 10 mg kg−1
per day for seizure prophylaxis for 6 months after the
operation. During the first 4 months following surgery,
he had no seizures or pathological electroencephelog-
raphy (EEG) findings. Approximately 4 months after
the surgery while he was being treated with cranial
radiotherapy, he was readmitted to our hospital with
GTCS lasting 15 minutes. On admission, physical
examination was unremarkable and neurological ex-
amination revealed that he was mildly confused and
had retrograde amnesia but cranial nerves, motor and
sensory examinations were unremarkable in postictal
state. Interictal state whole neurological examina-
tion was normal. His interictal EEG showed almost
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continuous epileptic activity originating in the left
temporal lobe. A diagnosis of partial seizure with
secondary generalised tonic–clonic convulsions was
made and carbamazepine (15 mg kg−1 per day) was
added to the current regimen. After this first seizure,
GTCS and complex partial seizures recurred, and
therefore carbamazepine dose was increased and
phenobarbital (5 mg kg−1 per day) was added while
phenytoin was decreased gradually and stopped. After
3 years of epilepsy-free period, the patient was referred
to the Pediatric Endocrinology Unit for evaluation of
his obesity and pituitary functions. His physical exam-
ination revealed an obese boy with a weight of 58.5 kg
(>95th percentile) and a height of 135.1 cm (10th per-
centile). On laboratory tests, T3: 1.01 ng ml−1 (nor-
mal range (NR): 0.60–1.81), T4: 8.7µg dl−1 (NR:
4.5–12.6), free T3 (fT3): 2.32 pg ml−1 (NR: 2.3–4.20),
free T4 (fT4): 0.9 ng ml−1 (NR: 0.9–2.0) and thy-
rotropin stimulating hormone (TSH): 3.69 mIU l−1
(NR: 0.35–5.5) which indicated a mild central hy-
pothyroidism. Growth hormone (GH) provocative
test with insulin hypoglycemia revealed that he had
inadequate GH but sufficient cortisol response to
hypoglycemia. Therefore, he was diagnosed with
central hypothyroidism and hyposomatotropism and
was started on l-thyroxine medication of 25µg per
day and the dose was increased gradually to 100µg
per day.
Two weeks after initiation of l-thyroxine treatment,
the patient began to experience pre-symptoms such
as epigastric discomfort and dizziness and panic reac-
tion like episodes. Following these symptoms usually
in the morning hours, he experiences an urge to run
forward without any rotation and then contractions
of his left extremity. According to his parents’ ob-
servation, if he was erect during the episode, he ran
for 20–45 seconds, then took a deep breath and the
seizure stopped. This new type of seizure started a few
weeks after the initiation of l-thyroxine treatment.
The frequency of seizures increased with increasing
dosage of l-thyroxine and reached up to seven to
eight seizures per day. The parents have noticed that
when the l-thyroxine dose was decreased to 75µg
per day by the parents, the daily number of seizures
decreased as well. Re-evaluation of his new onset
seizure activity has shown that his blood chemistry
results, EKG, cranial and pituitary MRI were all nor-
mal, except operation and maybe cranial radiotherapy
marks on MRI. Phenobarbital and carbamazepine
serum concentrations were in effective doses. A rou-
tine eight-channel EEG showed no epileptic focus,
but during the EEG tracing, the patient had a seizure
lasting for about 40 seconds. A long-term video-EEG
monitoring with long-term awake and sleeping period
were performed also. These EEG tracings demon-
strated infrequent discharges of sharp and slow
wave complexes, especially FP2–F8 channels during
awaken period and 2–2.5 Hz focal discharges at the
end of rapid eyes movement (REM)-I and non-REM
changing period, respectively (Figs 1 and 2). Valproic
acid was added at a dose of 10 mg kg−1 per day to the
antiepileptic regimen of carbamazepine while phe-
nobarbital was discontinued gradually. The parents
discontinued l-thyroxine medication completely for 3
weeks and a repeat thyroid function tests showed fT4:
0.70 ng ml−1 (NR: 0.9–2.0), TT3: 0.78 ng ml−1 (NR:
0.60–1.81), TT4: 3.6µg dl−1 (NR: 4.5–12.6) and
TSH: 5.85 mIU l−1 (NR: 0.35–5.5) which indicated
that he has central hypothyroidism. While he was
seizure free when l-thyroxine medication was dis-
continued, he still would need l-thyroxine treatment
for his central hypothyroidism. Therefore, he was
started on 25µg per day of l-thyroxine and the dose
will be adjusted more gradually and meticulously to
avoid provocation of his seizures.
DISCUSSION
The corner stone of the definition of HMS are motor
manifestations, which consist of organised move-
ments affecting especially the proximal muscles of
the limbs10. HSM are involuntary contractions lasting
for about 14–44 seconds with associated repetitive
movements, simple automatism, complex automatism
and contractions of motor muscles of tongue. In about
80% of patients, an aura with somatosensory findings
are experienced. According to the clinical findings and
presenting symptoms, HMS are classified as tonic,
hypermotor, tonic + hypermotor, pure hypertonic
seizures10. In our case, EEG and video EEG monitori-
sation findings as well as description of the episodes
by the parents were consistent with hypermotor tonic
seizures with aura originating from frontal cortex.
There are numerous factors that predispose patients
with brain tumours for having seizures. Some of these
factors are intrinsic to the disease while others are due
to primary or secondary effects of treatment such as
radiation therapy. In our patient, we investigated the
factors that may provoke or cause seizures such as pri-
mary recurrence of cranial tumor, presence of cranial
lesions secondary to radiotherapy or metabolic distur-
bances but no precipitating factor was demonstrated.
However, clinically there was a strong association be-
tween initiation or dosage of l-thyroxine treatment
and seizure activity.
There have been few reports in the literature demon-
strating the association between the rapid attainment
of l-thyroxine dosage and occurrence of seizures in
predisposed patients5. Although the cause of this as-
sociation has not been well understood, there are some
proposed mechanisms.
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Fig. 1: EEG showing the right frontal hemisphere epileptic focus especially FP2 (bipolar derivation) with spike and slow wave complexes of 2–2.5 Hz (transversal 30.0 mm second−1,
300.0µV cm−1, 70 Hz).
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Fig. 2: EEG showing the right frontal hemisphere epileptic focus especially FP2 and F8 channels (average montage) with spike and slow wave complexes of 2–2.5 Hz (average,
30.0 mm second−1, 300.0µV cm−1, 70 Hz).
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There were reports that did not show elevation
of TSH after seizure activity11–13. In contrast, Roa
et al.14 have noted elevated TSH levels that re-
turned to baseline 2 hours after seizures only in
epileptic patients. On the other hand, results of Kim
et al.15 demonstrated that thyroid hormone plays
a modulatory role in the seizure-induced changes
of neurotrophin-3 mRNA expression found in the
dentate gyrus. Elevated TRH contents were demon-
strated in rat brain of both electrical stimulated and
kainic acid-induced seizure models16. Furthermore,
radioimmunoassay measurements revealed an in-
creased hippocampal TRH concentration after seizure
activity16, 17. This prolonged elevation of TRH fol-
lowing recurrent seizure activity may be indicative
of a homeostatic response to convulsion, since TRH
can selectively reduce glutamate-induced excitation
of cortical neurones17, 18. Since our patient has a
central hypothyroidism most probably secondary to
hypothalamic dysfunction, decreased TRH secretion
due to l-thyroxine medication may not be the mecha-
nism responsible for his l-thyroxine-induced seizures
since he probably had decreased TRH even before
l-thyroxine treatment.
Another proposed mechanism for l-thyroxine-
induced seizures is that l-thyroxine has been found
to decrease the number of cortical benzodiazepin
receptors19. Since our patient was on phenobarbital
while he was started on l-thyroxine, this mechanism
may be responsible for the seizures of our patient
precipitated by l-thyroxine medication.
Although the mechanism how l-thyroxine treatment
induces HMS is not well known; it has been reported
that in patients with petit mal status and JMCE, it
may precipitate petit mal seizures4, 5. This condition
may be due to inadequate antiepileptic dosage when
l-thyroxine medication has been started, possibly
due to changes in pharmacokinetics or bioavailabil-
ity without changing the serum concentration of
antiepileptic medications.
In conclusion, we would like to emphasize that,
l-thyroxine medication may precipitate seizures in
epileptic patients and therefore, when l-thyroxine
treatment is required in epileptic patients, it should
be started in low dose and monitored very carefully
to avoid precipitation of seizures and potentially of
status epilepticus. Furthermore, the dosage of anti-
convulsants may have to be increased, especially in
patients with HMS, petit mal or JMCE.
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